Selected Start-Ups (5/01)
In Vivo summarizes the technology of several recently founded companies: Aptus Genomics Inc. is developing a platform to identify, qualify, and patent human cell surface receptor genes. Raven Biotechnologies Inc. spin-off bioMosaic Systems Inc. will develop Raven's CellArray cell-based high-throughput screening system. IntelliServices Inc. is building a suite of ASP-based software solutions for physicians. Spine Wave Inc. will develop and commercialize a minimally-invasive method for spinal disc repair. 20/20 Gene Systems Inc. is building protein analysis tools for determining the molecular fingerprint of a patient sample and comparing it to archived information from a larger patient population. Xcel Pharmaceuticals Inc. will in-license pharmaceuticals for niche therapeutic markets, initially focusing on neurology.
You may also be interested in...
Not Your Grandfather’s CAPA: Case For Quality Pilot Gives Corrective And Preventive Action A Facelift
Big changes are afoot when it comes to CAPA. Ten medtech manufacturing sites are playing in a pilot program that uses a novel framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach that separates higher-risk events from others that don’t need to be elevated to the level of a traditional CAPA. Medtronic quality/regulatory expert Kathryn Merrill weighs in.
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.